Human pharmacokinetics of an analogue of atrial natriuretic factor |
| |
Authors: | S. H. Ingwersen H. Eiskjaer M. Schmiegelow E. B. Pedersen |
| |
Affiliation: | (1) Pharmacokineties Preclinical Development, CNS Division Novo Nordisk A/S, DK-2760 Maaloev, Denmark;(2) Clinical Research, CNS Division, Novo Nordisk A/S, Maaloev, Denmark;(3) Department of Medicine and Nephrology C, Skejby University Hospital, Aarhus N, Denmark |
| |
Abstract: | Summary The pharmacokinetics of ANP-270, a 26 amino acid analogue of alpha human natriuretic factor (-hANF) with a prolonged effect on isolated arterial preparations has been studied in 40 healthy males, in a doubleblind placebo controlled investigation. Placebo or ANP-270 0.3, 1.5 or 3.0 g/kg were given by intravenous bolus injection, each to groups of 10 subjects. Blood samples were assayed for ANP-270 by a specific sandwich ELISA.The disappearance of ANP-270 from plasma followed a two-compartment decay, with mean distribution and elimination half-lives of 2.6 min (n = 30) and 10.6 min (n=20), respectively. These estimates were similar to those obtained by other investigators for -hANF. Their brevity explains the lack of a prolonged effect of ANP-270 in vivo compared to -hANF. |
| |
Keywords: | Atrial natriuretic factor ANP-270, P-ANP, NNC-70-0270, pharmacokinetics, assay method |
本文献已被 SpringerLink 等数据库收录! |
|